Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New 52-week intraday high ($12.76) today.
New 52-week closing high ($12.18) today.
New 52-week intraday high ($12.44) today.
New 52-week intraday high ($12.17) and closing high ($12.11) today.
New 52-week closing high ($11.355) today.
Four trial results projected to be released third quarter. This could explain run up, but I wonder if there is something else more imminent like finding for Ebola or MERS.
New 52-week intraday high ($11.45) and closing high ($11.19) today.
New 52-week intraday high ($11.16) and closing high ($11.11) today.
New 52-week intraday high ($10.00) and closing high ($9.96) today.
Heavy volume and great price action. Might set new 52-week high today (and see $10 soon). Looks like Modi is finally done selling. Wonder if some gov't agency is going to fund NVAX's MERS vaccine, not that this should be huge deal for NVAX compared to RSV and flu data coming in third quarter. Whatever the reason for the move today, nice to see testing the highs again.
Be careful what you wish for.
Mezzanine financing can be toxic depending on the terms. That could send the share price into a death spiral. Many OTC companies that participate in that type of financing have to do it on the financiers terms, not the company's. If they made a deal with Asher Enterprises, or one of the other common toxic financiers, count BION for dead. Asher would drive the share price down and then ultimately be able to convert the debt into millions upon millions of shares (the lower they can drive the share price, the more free-trading shares they would get to flood the market with).
BION's best bet is to get a traditional type of loan, but it seems to me that they are probably existing by issuing shares. It seems like whenever they have a traditional type of debt note due, they have no cash to pay for it.
This is a very nice addition to the Board. NVAX continues to bring in strategic players to prepare for commercialization. That way once these Ph2 (and, subsequently, Ph3) trials are completed, and assuming FDA approval, they will be able to hit the ground running and really get their vaccines some market share.
Novavax Appoints Gail Boudreaux to Board
GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K. Boudreaux to its Board of Directors.
“We are delighted to welcome Gail to Novavax’ Board,” said Stanley C. Erck, President and CEO of Novavax. “Her outstanding leadership and business experience will be important to our continued growth and success. Gail’s insight on health payors will be particularly important as we continue to move towards commercialization of our vaccines.”
Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience includes more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is currently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.
“I am very happy to be joining Novavax at such an exciting time,” said Ms. Boudreaux. “I look forward to helping the company achieve its goal to develop and deliver safe and effective vaccines to improve global heath.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax, Inc.
He covered, fortunately for him. Check his post from June 1. Posting from my phone, otherwise I'd give you link.
I love your priorities, TW (family and faith). Best of luck with your investment. I'm praying it all works out for you and all the longs. I sold mine for a loss last year, so I hope you all get some profit!
God bless!
Well, now we know why those large blocks went Friday and today: because Modi sold again. There was speculation on the NVAX message board on Yahoo! that those blocks may have been Modi selling. Turns out to be correct.
The question now is who bought them because there must have been a big buyer lined up to absorb that huge block, as the price would have probably dropped much more considering the large sales in such a short time period. The stock has performed well given the selling. There are so many catalysts coming in the third quarter, so Modi is probably leaving lots of $$$ on the table. He did the same thing a year or so ago and ultimately sold too low. Would have made much more had he just held longer.
He probably just needed money now, but I hope he ends up regretting the timing of his sales because that'll mean we get great results on RSV maternal, RSV elderly, and seasonal flu. I bet he'll wish he sold in fourth quarter rather than now. He hasn't timed sales very well.
Does anybody remember some kind of info from BION (probably over the past year), in which they stated they settled/came to an agreement re the whole HIDE thing by paying some money out to once and for all "let the skeletons out of the closet" and put some closure to that? I can't remember if that was thru a PR or just buried in a quarterly or annual report. Secondly, is this the agreement that BION apparently hasn't followed through on and is the point of contention that Roni911 (Ronald Fussman) has issue with? Sorry I haven't followed as closely the details of BION since last Summer/Fall.
TIA.
Below are a few helpful links I saved as favorites anytime I wanted to refresh my memory on the HIDE shell. Some of the links refer back to other links, so read those as well as they are also helpful.
A few days ago I sent a message to "nodummy" to get his insight. His knowledge of penny stock scams is unparalleled. The reason I emailed him was b/c I was particularly interested in Traderwebb's post about contacting Adam Friedman if anybody wanted to purchase a bunch of shares at a discount from somebody who was liquidating his/her position. I have never heard of that and wonder if it's even legal. I was hoping to get his thoughts on that. Then all this other crazy stuff started being posted about Annon, and it it got even jucier. Nodummy is a very busy person, so I don't know if he'll be able to respond; but hopefully he can.
Anyway, here are the links:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72963572" rel="nofollow" target="_blank" >http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72963572
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72960217" rel="nofollow" target="_blank" >http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72960217
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71432478" rel="nofollow" target="_blank" >http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71432478
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72958170" rel="nofollow" target="_blank" >http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72958170
From what I have gleaned, market makers use computer algorithms to occasionally take out a bunch of stop losses thereby causing modest/big drop in stock price. Sometimes that tactic can be used to accumulate large chunk of shares for funds, etc. Those entities or funds want a little discount on the shares, if possible, (who wouldn't) esp since they're purchasing large block. I think market makers can work with them to collect shares for them at specified price. All my opinion...not gospel.
Usually that's an entity buying those shares. Market makers probably took out a lot of retail's stop losses in order to accumulate that large chunk of shares at a nice discount for the acquirer. I suspect (hope) the share price will recover. It actually did pretty well overall considering that volume sold. Plus, it has a wall at the $9.00 level it seems anyway.
Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today's Pre-NDA Meeting with the FDA
- Held pre-NDA meeting and agreed on rolling submission with the Agency -
- Will submit first two components of the NDA this week -
- Plans to complete the submission by mid-year -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 19, 2015--
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD). Sarepta has agreed with the Agency to initiate a rolling NDA submission and will submit the non-clinical and CMC components of the NDA by the end of this week. As previously announced, Sarepta plans to submit the final component of the NDA by mid-year 2015.
"We will initiate a rolling NDA submission to facilitate the regulatory review of the NDA," said Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer. "The initiation of our NDA submission for eteplirsen marks a significant milestone for the Duchenne community and we look forward to completing the submission by the middle of the year and to continuing to work with the Agency towards the goal of providing treatments to patients as quickly as possible."
About Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. For more information, please visit us at www.sarepta.com.
Forward-Looking Statements
This press release contains statements that are forward looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "may," "intends," "prepares," "looks," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to Sarepta's plans to initiate a rolling NDA for eteplirsen, facilitate the regulatory review process, submit the non-clinical and CMC components of the NDA by end of this week, complete the final component of the NDA by mid-year 2015 and the Company's plans to continue working with the Agency towards the goal of providing treatments to patients as quickly as possible.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may be delayed in or may not be able to complete our planned NDA submission for eteplirsen; even if we complete our eteplirsen NDA submission we may not be able to comply with all FDA requests in a timely manner or at all and the FDA may determine that the submission does not qualify for filing or approval; the additional information and data we collect or have collected for the eteplirsen NDA submission may not be consistent with prior data or results or may not support an eteplirsen NDA filing or approval; there may be delays in our projected timelines and our expectations may not be accurate with respect to a potential commercialization of eteplirsen for various reasons, including possible limitations of Company resources and regulatory or agency decisions, scale-up of manufacturing may not be successful, we may lack the funding necessary to commercialize eteplirsen or any of our product candidates, the results of the additional eteplirsen trials the Company conducts may not support an NDA filing or approval for eteplirsen and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta, which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150519007054/en/
CONTACT: Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Ryan Flinn, 415-946-1059
Mobile: 510-207-7616
rflinn@w2ogroup.com
SOURCE: Sarepta Therapeutics, Inc.
Copyright Business Wire 2015
(END) Dow Jones Newswires
May 19, 2015 16:00 ET (20:00 GMT)
Exactly. That's how I remember it, too.
Interesting. Based on his background, it looks like he could be used to clean up their books from the dirty shell/reverse merger/insider enrichment days. Or maybe there is work to be done post-BK with lingering issues we're not privy to?
Very intriguing why he's on board based on his bio. A PR detailing why he was hired will be helpful.
Definitely agree.
I seem to remember listening to the first-ever Bionitrogen conference call and hearing BK say that they were not that far away from uplisting. That call was quite some time ago (I think two years ago), but it still hasn't happened. Not sure how long it takes to get the finances in order, as this is not my specialty, but pink sheet companies often speak speak about moving up into different tiers or to a major exchange but never do. Certainly would bring more credibility to them and bring more investors, but I'm not holding my breath yet.
And, no, I am not short this stock!
In my opinion, the reason the stock dropped -- if truly due to the Pennsylvania site falling through -- isn't due to losing a potential site. They have a bunch of potential sites. It's in the fact that they lost it because of failing to show financials. We can never trust companies' financials if they trade on the pink sheets, not even what they release in their quarterly and annual reports. There's no strict requirements or accountability. Clearly, that commission was suspicious enough about them to require that type of info.
They probably couldn't provide financials to that Pennsylvania entity because their financials are all corrupt. Don't believe it when BION tries to spin it that they realized there was something wrong with that site anyways so there was no need to provide financials because they were going to walk away themselves. It's like, "No, I dumped him. He didn't dump me."
I was a super long like most of you. I even flew to Florida and checked out first potential site and met with Bionitrogen, myself. I was warned by plenty of people about investing in this company from the beginning of it's initial pump and dump. I chose not to listen, thinking this company was different. Well, I've come to the sad realization that they aren't very different. That's not to say that there aren't opportunities to profit from trading this stock, so I truly hope all the holdout longs from 2012, like I was, can get out with their shirts and not lose much, or even better, make a few bucks. As you all probably know and do already, just don't invest more here than you're willing to lose.
I'm not surprised that BioNitrogen didn't release financials. That's why I got out last September because I think they're hiding a lot of things financially...like all the insider enrichment from the beginning and maybe still going on. If BioNitrogen doesn't have a good reason not to release financials to that entity (other than corruption), then Carlos Contreras can say all he wants about uplisting to another exchange and all the work going into tidying up financials. An uplist will probably never happen.
BION may not necessarily be selling shares actively now, but, if anything, it's probably shares that were issued to 3rd parties for covering BION's expenses that are now being dumped on the market. The way I think people should view it is that shares are basically given away to 3rd parties (for free), then those entities can sell it at whatever price they want. Free shares sold at $0.03 is still nice for them. It can drive stock price down because they have less incentive to keep share price up when demand is low. Somebody, however, is also buying those shares, too, remember.
Why the sudden change? Very curious.
I find it puzzling because they brought him back in the fold, albeit in a reduced role, almost immediately after that whole run-in with the law. Now he's mysteriously gone?
No PR about this yet. I suppose one will be coming.
Well, they were supposed to be funded into 2016, but I guess they figure they should raise money when they can (not when they have to).
Novavax Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md., March 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer to sell, subject to market and other conditions, $175 million of its common stock in an underwritten public offering. As part of this offering Novavax intends to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock.
J.P. Morgan and Citigroup are acting as joint book-running managers of the offering.
All shares being offered are to be sold by Novavax with the net proceeds from the offering to be used for the advancement of Novavax' lead vaccine candidates, including the preparation and potential initiation of Phase 3 clinical trials of its elderly RSV and maternal RSV programs, as well as its other clinical and preclinical research programs and general corporate purposes, including working capital, product development, manufacturing and process development expenditures and capital expenditures, as well as acquisitions and other strategic purposes.
The securities described above are being offered by Novavax pursuant to its registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering may be made only by means of the preliminary prospectus supplement and the prospectus relating to the proposed offering, copies of which may be obtained, when available, from J.P. Morgan and Citigroup, Attention: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: (866) 803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines.
Forward-Looking Statements
Statements contained in this release, including those relating to the sale of common stock, and those statements using words such as "expects" and "intends" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully complete the offering on terms and conditions satisfactory to us; the possible adverse impact on the market price of our shares of common stock due to the dilutive effect of the securities to be sold in the offering; our planned use of the proceeds from this offering; capital market risks; our ability to raise additional capital when needed; and other risk factors identified from time to time in the reports we file with Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
CONTACT: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000
Source: Novavax, Inc.
Yet another addition to the NVAX team from MedImmune, who makes Synagis.
Novavax Appoints Brian Rosen as Vice President, Government Affairs
GAITHERSBURG, Md., March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates.
Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide. He previously developed and ran the Government Affairs, Policy and Alliance Development functions for MedImmune, which developed Synagis, a monoclonal antibody used to prevent RSV disease in premature newborns, and FluMist, a live attenuated influenza vaccine.
"The healthcare landscape is constantly changing and supportive vaccine policy requires diligent attention and coordination in concert with Novavax' commercialization plans. Brian's extensive experience, particularly with RSV and influenza, is critical to planning and executing a commercial launch of our vaccines," said John Trizzino, SVP, Commercial Operations. "Brian is a key addition to our management team and brings valuable perspective that I am confident will contribute to bringing our novel vaccines to market."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn
Senior Manager, Investor Relations
Novavax, Inc.
ir@novavax.com
240-268-2000
Exactly. They have a lot going for them.
Good interview. Focused mainly on Ebola, but he, importantly, touched on their technology that allows them to take nanoparticles (proteins) and make vaccines faster than anybody else.
I think Dew predicted that ENTA would be a bargain at that $17-19 price, since he thought they would be very likely to get superb Phase 3 results given their Phase 2 results. I seem to remember him saying that HCV the data is reproducible. I could be misremembering.
Definitely great news. The run up in share price, partly in anticipation of this, has held surprisingly well, despite some likely profit taking. I think there is a nice new base in the $7s and $8s with retail and maybe institutional buying.
Agreed, that's exactly what I was saying. A little information to be perfectly clear about things would have gone a long way, rather than rampant speculation. BTW, what is an "NDA." I invest mainly in biotechs now, so an NDA to me is a New Drug Application that gets sent to the FDA. Clearly, that's not what Adam was referring to.